NERVGEN PHARMA CORP. Research and Development Expense
NERVGEN PHARMA CORP. (NGEN) reported Research and Development Expense of CAD 13.91 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-31
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-12-31 | 13.91M CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 15.81M CAD 40-F · filed 2026-03-31 |